New approaches to hematopoietic cell transplantation in oncology (Q35064139)

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

North American Multicenter Study on flow cytometric enumeration of CD34+ hematopoietic stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Enumeration of CD34-Positive Stem Cells: Evaluation and Comparison of Three Methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Standardization of the CFU-GM assay using hematopoietic growth factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Granulocyte colony-stimulating factor alone at 20 micrograms/kg vs. 10 micrograms/kg for peripheral blood stem cell mobilization in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Clinical collection and use of peripheral blood stem cells in pediatric patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Safe and efficient peripheral blood stem cell collection in the smallest of children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Mobilization/harvest and transplantation with blood stem cells, manipulated or unmanipulated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Feasibility of peripheral blood stem cell (PBSC) and peripheral blood mononuclear cell (PBMNC) separation in children with a body weight below 20 KG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Collection and use of peripheral blood stem cells in young children with refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Factors influencing the timing of peripheral blood stem cell collection (PBSC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

PBSC collection after high dose chemotherapy followed by G-CSF in patients with malignancies: analysis of results regarding factors affecting the yield of hemopoietic progenitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Positive Selection and Transplantation of Peripheral CD34+ Progenitor Cells: Feasibility and Purging Efficacy in Pediatric Patients with Neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Positive selection of autologous peripheral blood stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Outcomes among 562 recipients of placental-blood transplants from unrelated donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Banking and transplantation of unrelated donor umbilical cord blood: status of the National Heart, Lung, and Blood Institute-sponsored trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Acquired multicellular-mediated resistance to alkylating agents in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose therapy/stem cell support: comparison of mice and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and Marrow Transplant Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Cataracts in patients receiving stem cell transplantation after conditioning with total body irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Cataract after total body irradiation and bone marrow transplantation: degree of visual impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Non-myeloablative stem cell transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Bl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Haematopoietic cell transplantation as immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: a cooperative study of the Groupe d'Etude de la Greffe de Moelle Osseuse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Early response to therapy and outcome in childhood acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) and the Gruppo Italiano Trapianto di Midollo Osse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

A second course of treatment for childhood acute lymphoblastic leukaemia: long-term follow-up is needed to assess results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

BONE-MARROW TRANSPLANTATION IN HIGH-RISK ACUTE LYMPHOBLASTIC LEUKAEMIA IN FIRST AND SECOND REMISSION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Outcome after first relapse in children with acute lymphoblastic leukemia: A population‐based study of 315 patients from the nordic society of pediatric hematology and oncology (NOPHO)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Treatment of isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. Associazione Italiana Ematologia ed Oncologia Pediatrica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs leukemia effect, and post-transplant im

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous Transplantation with CD52 Monoclonal Antibody-Purged Marrow for Acute Lymphoblastic Leukemia: Long-Term Follow-Up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Grup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Definition of a standard-risk group in children with AML

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the Internation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Acute myeloid leukemia: therapeutic indications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Feasibility study of autologous peripheral blood stem cell transplantation for the treatment of childhood acute myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The role of thiotepa in autologous bone marrow transplantation for acute leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft-versus-leukemia and graft-versus-host effects with cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Preliminary Results of Treatment with Filgrastim for Relapse of Leukemia and Myelodysplasia after Allogeneic Bone Marrow Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

AraC-based pharmacotherapy of chronic myeloid leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic marrow transplantation for chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic bone marrow transplantation in children with chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Therapy of childhood acute myelogenous leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Monoclonal antibody-based therapy for neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Age-specific survival after Hodgkin's disease in a population-based cohort (United States).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Characterization and outcome of "hard to mobilize"' lymphoma patients undergoing autologous stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Prolonged complete remission following high dose chemotherapy of burkitt's lymphoma in relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Bone marrow transplantation for non-Hodgkin's lymphoma in children and young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose cyclophosphamide, adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous stem cell transplantation for high-risk pediatric solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Clinical outcome of high-dose chemotherapy combined with peripheral blood stem cell transplantation for male germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9

Autologous bone marrow transplantation in childhood acute lymphoid leukemia with use of purging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900094-9